1
9
(
sextet, 7.5 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H); F NMR (376 MHz, CDCl
3
) δ -81.40 (t, 6F, J =
1
1
0.1 Hz), -113.95 (t, 4F, J = 13.4 Hz), -122.38 (s, 12F), -123.22 (s, 4F), -124.06 (s, 4F), -
3
1
26.68 (d, 4F, J = 6.2 Hz); P NMR (162 MHz, CDCl
3
) δ -0.49.
1
-Hexyl-3-methylimidazolium di(1H,1H,2H,2H-perfluorodecyl)phosphate
1
H NMR (400 MHz, CDCl
3
): δ 10.41 (s, 1H), 7.28 (s, 2H), 4.29 (t, J = 7.3 Hz, 2H), 4.06 (s,
3
1
H), 3.99 (t, J = 6.4 Hz, 2H), 3.90 (tt, J = 13.4; 6.1 Hz, 4H), 2.40 (tt, J = 18.5, 6.1 Hz, 4H),
19
.31 – 1.19 (m, 6H), 0.96 (t, J = 7.4 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H); F NMR (376 MHz,
): δ -81.73 (t, 6F, J = 10.1 Hz), -113.44 (t, 4F, J = 13.7 Hz), -121.69 (s, 12F), -122.71
CDCl
3
3
1
(s, 4F), -123.68 (s, 4F), -126.09 (s, 4F); P NMR (162 MHz, CDCl
3
): δ -0.50.
1
-Methyl-3-octylimidazolium di(1H,1H,2H,2H-perfluorodecyl) phosphate
1
NMR H (CDCl
3
, 400 MHz): δ 10.03 (s, 1H); 7.59 (s, 1H), 7.51 (s, 1H), 4.17 (t, J=6.8 Hz,
2
2
H), 3.99 (s, 3H), 3.84 (dt, J = 17.2, 6.3 Hz, 4H), 2.40 (tt, J = 18.0, 6.3 Hz, 4H) 1.76-1.77 (m,
1
9
H); 1.09-1.17 (m, 10H); 0.70 (t, J=6.4Hz, 3H); F NMR (376 MHz, CDCl ): δ -80.84 (t, 6F,
3
J=10.2 Hz), -112.50 (s, 12F), -113.56 ((t, 4F, J = 13.7 Hz), 121.71 (s, 4F), -122.73 (s, 4F), -
3
1
1
23.70 (s, 4F), -126.08 (s, 4F); P NMR (162 MHz, CDCl
3
): δ -0.49.
1
-Decyl-3-methylimidazolium di(1H,1H,2H,2H-perfluorodecyl) phosphate
1
H NMR (400 MHz, CDCl
3
): δ 10.12 (s, 1H); 7.67 (s, 1H);7.28 (s, 1H) 4.25 (t, J=7.6 Hz, 2H);
4
1
.12 (s, 3H) 3.78 (t, J = 7.6 Hz, 4H); 2.33 (tt, J=17.1; 7.6 Hz, 4H) 1.73 (quintet, 6.8 Hz, 2H);
1
9
.38 – 1,19 (m, 14H); 0.91 (t, J = 7.4 Hz, 3H); F NMR (376 MHz, CDCl ): δ -80.84 (t, 6F,
3
J=11 Hz), -112.45 (s, 4F), -113.53 (d, 12F), -121.77 (s, 4F), -122.78 (s, 4F), -123.75 (s, 4F), -
3
1
1
26.15 (s, 4F); P NMR (162 MHz, CDCl
3
): δ -0.50.
1
,3-Dibutylimidazolium di(1H,1H,2H,2H-perfluorodecyl) phosphate
1
H NMR (400 MHz, CDCl
3
): δ 9.18 (s, 1H), 7.79 (s, 1H), 7.51 (s, 1H), 4.94 (t, J= 7.3 Hz,
4
H), 3.99 (t, J = 6.1 Hz, 4H), 3.90 (tt, J = 13.0, 6.1 Hz, 4H), 2.09 (m, 4H), 1.30 (m, 4H), 0.90
1
9
(
t, J = 7.4 Hz, 6H); F NMR (376 MHz, CDCl
2F), -121.69 (s, 4F), -122.71 (s, 4F), -123.68 (s, 4F), -126.09 (s, 4F); P NMR (162 MHz,
CDCl ): δ -0.49.
3
): δ -80.73 (t, 6F, J= 11 Hz), -113.44 (m,
3
1
1
3
1
-Butyl-3-hexylimidazolium di(1H,1H,2H,2H-perfluorodecyl) phosphate
1
H NMR (400 MHz, CDCl
3
): δ 10.22 (s, 1H), 7.28 (s, 1H), 7.25 (s, 1H), 4.17 (m, 4H), 3.70 (t,
J=6.9 Hz, 4H), 2.28 (tt, J = 17.4 Hz, 6.9 Hz, 4H), 1.78 – 1.54 (m, 4H), 1.39 – 0.89 (m, 8H),
1
9
0
8
4
.93 (t, J = 7.4 Hz, 3H), 0.77 (t, J = 6.7 Hz, 3H); F NMR (376 MHz, CDCl
3
): δ -80.83, -
1.01 (m, 6F), -113.56 (s, 4F), -121.87 (s, 12F), -122.86 (s, 4F), -123.77 (s, 4F), -126.21(s,
3
1
F); P NMR (162 MHz, CDCl
3
): δ -0.51.
1
-Butyl-3-octylimidazolium di(1H,1H,2H,2H-perfluorodecyl) phosphate
1
H NMR (400 MHz, CDCl
3
): δ 10.09 (s, 1H), 7.29 (s, 1H), 7.27 (s, 1H), 7.24 (s, 1H), 4.21 (m,
4
8
H), 3.83 (t, J =7.0 Hz, 4H), 2.35 (tt, J = 18.8 Hz, 7.0 Hz, 4H), 1.92 – 1.73 (m, 4H), 1.39 – 0.
1
9
9 (m, 12H), 0.92 (t, J = 7.4 Hz, 3H), 0.81 (t, J = 6.7 Hz, 3H); F NMR (376 MHz, CDCl ): δ
3
-
1
80.83, -81.01 (m, 6F), -113.84 (s, 4F), -122.04 (s, 12F), -123.05 (s, 4F), -123.93 (s, 4F), -
3
1
26.30 (s, 4F); P NMR (162 MHz, CDCl
3
): δ -0.48
1
-Butyl-3-decylimidazolium di(1H,1H,2H,2H-perfluorooctyl) phosphate
1
H NMR (400 MHz, CDCl ): δ 10.59 (s, 1H); 7.14 (d, J = 1.0 Hz, 2H); 4.16 (dt, 4H, J = 15.4,
3
7
2
.1 Hz); 3.70 (t, J = 7.1 Hz, 3H), 2.62 –
.26 (m, 4H), 1,86 (dq, J = 12.7, 7.6 Hz,
1
1